Results 91 to 100 of about 1,113 (191)
Clinical Ophthalmology, 2017 Habiba Saedon,1 Astha Anand,1 Yit C Yang1,2 1Department of Ophthalmology, Royal Wolverhampton NHS Trust, Wolverhampton, West Midlands, 2School of Life and Health Sciences, Aston University, Birmingham, UK Abstract: The first-line therapy for patients ...
Saedon H, Anand A, Yang YC
doaj
Journal of Ophthalmic Inflammation and Infection, 2019 Background A retrospective observational clinical study to evaluate the safety and effectiveness of the injectable 0.19-mg fluocinolone acetonide intravitreal implant (ILUVIEN) in the treatment of non-infectious uveitic macular edema.
Lea F. Weber +6 more
doaj +1 more source
Sustained Release Intraocular Drug Delivery Devices for Treatment of Uveitis [PDF]
, 2011 Corticosteroids have been the mainstay of uveitis therapy. When intraocular inflammation is unresponsive to steroids, or steroid related side effects become a concern, steroid-sparing medications may be administered which can be classified into ...
Abdekhodaie, Mohammad Jafar +2 more
core +2 more sources
Langzeitbehandlung des diabetischen Makulaödems mittels Intravitrealer Fluocinolonacetonid-Injektion (Iluvien): Klinische Befunde und Spectral-Domain-optische-Kohärenztomographie-Untersuchung im Verlauf [PDF]
, 2021 Das Ziel der vorliegenden Arbeit ist die Untersuchung der Fluocinolonacetonid (Iluvien®) –Injektion als Therapiemöglichkeit der diabetischen Retinopathie an der Augenklinik der Universität Erlangen.
Mulica, Markus
core +1 more source
International Medical Case Reports Journal, 2019 Joseph M ConeyRetina Associates of Cleveland, Cleveland, OH, USAObjective: To assess the effectiveness, safety, and treatment burden in eyes with persistent diabetic macular edema (DME) for up to 1 year after administration of 0.19 mg fluocinolone ...
Coney JM
doaj
Treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyes [PDF]
, 2018 AIM: To report real-life data on the use of an intravitreal fluocinolone acetonide implant in the treatment of refractory diabetic macular edema (DME) in pars plana vitrectomized (PPV) and non-PPV eyes.
Alan Hawrami +4 more
core +1 more source
Diabetes, Metabolic Syndrome and Obesity, 2015 Zafer Cebeci, Nur KirDepartment of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Capa, Istanbul, TurkeyAbstract: Diabetic macular edema (DME) is the leading cause of sight-threatening complication in diabetic patients, and several ...
Cebeci Z, Kir N
doaj
Efficacy and safety of different doses of a slow release corticosteroid implant for macular edema
Drug Design, Development and Therapy, 2016 John Hall Medical Affairs, Alimera Sciences Ltd., Aldershot, Hampshire, UKI read “Efficacy and safety of different doses of a slow release corticosteroid implant for macular edema: meta-analysis of randomized controlled trials” published in ...
Hall J
doaj
Novel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye [PDF]
, 2013 This article reviews the new clinically relevant data regarding the intraocular treatment of non-infectious uveitis. Triamcinolone acetonide is the most commonly used intravitreal corticosteroid for treatment of uveitis and uveitic macular oedema.
Mikhail, Michael, Sallam, Ahmed
core +1 more source
Ophthalmic Inserts prepared either by Extrusion or by Freeze-Drying : Technological and Biopharmaceutical Characterization [PDF]
, 2015 The main goal of this thesis is the development of an ophthalmic biodegradable insert containing fluocinolone acetonide (FA), to apply in the posterior segment of the eye. The inserts under study were prepared using the hot-melt extrusion technique (HME).
TERRENI, ELEONORA
core